FDA
-
-
-
-
-
-
-
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Ardelyx (ARDX): Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH to be Presented
-
-
-
-
-
-
-
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
-
-
-
-
-
-
-
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
-
-
-
-
-
-
-
Ardelyx (ARDX) Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
-
-
-
-
-
-
-
Ardelyx (ARDX) Announces XPHOZAH now Available in the US
-
334,177 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


